Management of end-stage liver disease in chronic hepatitis B

Hui Hui Tan; Paul Martin

doi:10.1016/j.cld.2010.05.006

Management of end-stage liver disease in chronic hepatitis B

Hui Hui Tan, Paul Martin

Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.

Original language	English (US)
Pages (from-to)	477-493
Number of pages	17
Journal	Clinics in liver disease
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.cld.2010.05.006
State	Published - Aug 1 2010

Keywords

Antiviral therapy
Cirrhosis
End-stage liver disease
Hepatitis B
Liver transplantation

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2010.05.006

Fingerprint Dive into the research topics of 'Management of end-stage liver disease in chronic hepatitis B'. Together they form a unique fingerprint.

Cite this

@article{3a16b4c439724e319c25610d8b3e0880,

title = "Management of end-stage liver disease in chronic hepatitis B",

abstract = "The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.",

keywords = "Antiviral therapy, Cirrhosis, End-stage liver disease, Hepatitis B, Liver transplantation",

author = "Tan, {Hui Hui} and Paul Martin",

year = "2010",

month = aug,

day = "1",

doi = "10.1016/j.cld.2010.05.006",

language = "English (US)",

volume = "14",

pages = "477--493",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Management of end-stage liver disease in chronic hepatitis B

AU - Tan, Hui Hui

AU - Martin, Paul

PY - 2010/8/1

Y1 - 2010/8/1

N2 - The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.

AB - The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.

KW - Antiviral therapy

KW - Cirrhosis

KW - End-stage liver disease

KW - Hepatitis B

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=77954632240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954632240&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2010.05.006

DO - 10.1016/j.cld.2010.05.006

M3 - Review article

C2 - 20638026

AN - SCOPUS:77954632240

VL - 14

SP - 477

EP - 493

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -